fda approved tirzepatide online approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA says the tirzepatide weight-loss

GLP-1 Billing Quick Reference (2026) GLP-1 billing errors are among the fastest-growing sources of claim denials in 2026

(PubMed) Savitha S, Sivarajan K, Haripriya D, Kokilavani V, Panneerselvam C

You may experience appetite suppression within 1-2 weeks of starting the treatment

So, Im not too shocked that a lot of patients dropped the injections so early when the media makes it look that easy when its actually not

You can counter this side effect by starting with a lower dosage or taking the medication with food

Abstract Background: Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAP) as well as glucagon-like peptide-1 (GLP-1) have independently been implicated in irritable bowel syndrome (IBS) pathophysiology